Seeking Alpha
26 Jul 2026, 13:46 UTC · 8w ago
Verdict
Headline leans bullish. We score CLDX +1.00 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish
Celldex's EMBARQ-CSU 1 and 2 phase 3 trials completed enrollment six months ahead of schedule.
More positive than 92% of claims this week
Pivotal data for barzolvolimab is expected in September/October 2026, with a potential BLA filing in 2027.
Continue reading
5 related stories
More positive than 98% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 77% of claims this week
The company is advancing CDX-622, a bispecific TSLP & SCF inhibitor, with promising phase 1 safety and mechanism data.
More positive than 63% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company maintains a 'Strong Buy' rating due to rapid phase 3 enrollment and promising pipeline catalysts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−12.5%
Price is moving against the score
$30.88 vs $35.28 close before publication (Jul 24) · not market-adjusted
CLDX chart →
